Welcome to our dedicated page for AlphaTON Capital news (Ticker: ATON), a resource for investors and traders seeking the latest updates and insights on AlphaTON Capital stock.
AlphaTON Capital Corp (NASDAQ: ATON) generates news at the intersection of technology, digital assets, decentralized AI infrastructure, and advanced healthcare. The company describes itself as a public technology company scaling the Telegram super app while managing a strategic reserve of digital assets and building exposure to The Open Network (TON) ecosystem. Its announcements often combine capital markets activity with updates on AI compute deployments, Telegram-based applications, and tokenization initiatives.
Readers following ATON news can expect frequent coverage of financing transactions such as private placements, at-the-market offerings, and registered direct offerings supported by shelf registration statements. These items detail how AlphaTON raises capital to fund GPU deployments for Cocoon AI, expand data center capacity, and support working capital and general corporate purposes.
Another major category of AlphaTON news involves decentralized AI infrastructure. The company has issued multiple releases about securing and deploying NVIDIA H200, B200 and B300 GPUs, entering into a multi-year colocation agreement with atNorth in Sweden, and contributing confidential compute power to Telegram’s Cocoon AI network. These updates describe how AlphaTON is building privacy-preserving, decentralized AI infrastructure integrated with Telegram’s ecosystem.
News items also cover strategic investments and ecosystem partnerships, including investment in Alpha Liquid Terminal, plans for tokenized financial products, and initiatives like the #OwnYourNode program that aim to democratize GPU ownership. In addition, AlphaTON reports on its legacy biotech activities and its intention to launch a decentralized, AI-native biotech platform for rare cancers, starting with mesothelioma.
For investors and observers, the ATON news feed offers a way to track how the company combines digital asset treasury management, AI infrastructure build-out, Telegram-based financial applications, and biotech-related initiatives under a single Nasdaq-listed entity.
AlphaTON (Nasdaq: ATON) subsidiary Cyncado Therapeutics presented preclinical mesothelioma data showing selective A2B receptor inhibition produced direct anti-tumor effects across epithelial and non-epithelioid models. TT-4 monotherapy outperformed anti-PD-1 and TT-4 + anti-PD-1 achieved >90% tumor growth inhibition in vivo. Mechanistic readouts showed decreased pCREB and reduced tumor PD-L1. TT-4 is reported as IND-enabled and remains on track for first-patient dosing in Q1 2026. Cyncado will use these data to finalize clinical plans for mesothelioma.
AlphaTON Capital (Nasdaq: ATON) and Cyncado Therapeutics presented preclinical mesothelioma data on Oct 25, 2025 showing that selective A2B receptor antagonist TT-4 produced direct anti-tumor activity in epithelial and non-epithelial models, reduced pCREB and tumor PD-L1, modulated YAP signaling, and increased immune infiltration and tertiary lymphoid structures.
The poster reports TT-4 monotherapy exceeding anti-PD-1 in models and combination treatment further improving tumor control. The program is described as IND-enabled and on track for first-patient dosing in Q1 2026.
AlphaTON Capital (NASDAQ: ATON) appointed Wes Levitt as Chief Financial Officer, effective Oct 24, 2025. Levitt joins from Alpha Sigma Capital Advisors as former Co-CIO and previously served as Head of Strategy at Theta Labs and as CFO for a SPAC. He holds a B.S. in Economics and an MBA from Haas School of Business. At AlphaTON he will oversee finance, accounting, and capital markets operations and lead initiatives to optimize financial governance, scale investor communications, and support growth of the company’s global digital asset portfolio within the TON ecosystem.
AlphaTON Capital (Nasdaq: ATON) joined the Blockchain Game Alliance (BGA) on Oct 22, 2025 and expanded its Telegram/TON gaming strategy.
AlphaTON announced an intent to acquire a 51% equity stake in GAMEE, plus a planned token purchase, both subject to definitive documentation and approvals. The firm highlighted Telegram’s >1 billion monthly active users and the availability of TON Wallet to U.S. users as key distribution rails. AlphaTON will offer growth capital, launchpad/incubator support, go-to-market marketing, strategic partnerships, and a TON Gaming Builders track for BGA members to apply for funding and technical support.
AlphaTON Capital Corp (Nasdaq: ATON) and its oncology subsidiary Cyncado Therapeutics announced an AACR abstract (presented Oct 25, 2025) reporting that selective A2B (ADORA2B) receptor inhibition reduced adenosine-mediated PD-L1 expression in a human epithelioid mesothelioma cell line, linked to decreased pCREB. In an immunocompetent mesothelioma model, the investigational agent TT-4 as monotherapy outperformed anti-PD-1, and the TT-4 + anti-PD-1 combination showed significantly greater anti-tumor activity and increased T-cell infiltration. Additional data will be shown at the poster session in Boston on Saturday, October 25, 2025, 12:30–4:00 PM EDT.
AlphaTON Capital (NASDAQ: ATON) announced that Enzo Villani, Chief Investment Officer, will speak at the 10th Anniversary IASC World Changers Summit on October 20, 2025 at the Casina Pio IV in Vatican City.
Villani will deliver a 10-minute address on the intersection of ethics, innovation, and digital transformation, drawing on two decades of experience in finance, blockchain, and global impact. The Summit gathers global thought leaders to discuss ethical innovation, cooperation across nations and faiths, and sustainable, purpose-driven technology.
AlphaTON Capital (Nasdaq: ATON) sponsored and hosted the TOKEN2049 Singapore “Origins” Hackathon at Marina Bay Sands on October 15, 2025, awarding a US$25,000 prize pool paid in TON to global developers focused on AI, payments, and infrastructure.
Track leads and mentors selected winners across three tracks: AI (IntentHub 1st), Payments (Telepay 1st), and Infrastructure (Encrypted Prediction-Market Seeding 1st). AlphaTON said it will continue a global HackATON series to support TON builders with capital, mentorship, and go-to-market routes.
AlphaTON Capital (Nasdaq: ATON) CEO Brittany Kaiser will appear with Anthony Scaramucci on Schwab Network’s Trading 360 with Marley Kayden on October 14, 2025 at 11:30 a.m. ET. The live segment will discuss the evolving role of digital assets in modern finance and AlphaTON’s approach to funding cancer research using blockchain-based asset tokenization. The company describes tokenized assets as a way to connect investors and researchers and create new funding pathways. Viewers can watch the live discussion on Schwab Network.
AlphaTON Capital (Nasdaq: ATON) announced a strategic partnership with Morpheus AI on October 13, 2025 to make Morpheus the preferred AI infrastructure provider for AlphaTON portfolio companies building on TON and Telegram.
The MOU covers decentralized inference, a tools marketplace, and decentralized storage to accelerate agentic AI development and reduce integration time for AI agents. The deal highlights use of $MOR tokens within the ecosystem and a knowledge-sharing collaboration between the two firms.
AlphaTON Capital (NASDAQ: ATON) announced Nasdaq publicly congratulated the company for pioneering a blockchain-based cancer research tokenization initiative; the recognition was displayed on the Nasdaq Tower in Times Square on October 10, 2025. AlphaTON is partnering with Cyncado Therapeutics to fund oncology programs via tokenized assets, aiming to increase liquidity, improve transparency of fund allocation, lower investor minimums, and accelerate R&D timelines. The company said the model helped advance multiple research programs and that it plans to expand tokenization to more therapeutic areas and institutional partners.
FAQ
What is the current stock price of AlphaTON Capital (ATON)?
What is the market cap of AlphaTON Capital (ATON)?
